50% off Premium Yearly
Bristol Myers SquibbBMYDON'T BUYOct 23, 2023Stock price when the opinion was issued
As of Jun 18, 2026. Market Open.
Big on immune oncology and cardio. Technically doesn't look great, but eventually "the train will come along and collect the mail bag". Makes a ton of $$ in NA. Wide moat. Concerns about pipeline, but he thinks it's pretty good. Limited downside. Yield is 4.9%.
Good pricing power. Because products are so specialized, FDA puts them on sort of a fast track.
In the past quarter, They recently bought 3 companies, including Mirati, a small oncology company, and Karuna who may develop a wonder drug to treat schizophrenia. BMY needs to buy companies, because their top 3 drugs face steep patent cliffs, like a blood-clot drug, accounting for over 61% of 2023 (Jan-Sept)'s sales.
They don't have the drug pipeline that they used to have. Also, don't buy a stock only for the dividend.